Ingredients | Amount Per Serving |
---|---|
(Dry Diindolylmethane)
|
200 mg |
100 mg |
Gelatin, Rice powder
Below is general information about the effectiveness of the known ingredients contained in the product Estrovert. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
Below is general information about the safety of the known ingredients contained in the product Estrovert. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
There is insufficient reliable information available about the safety of chrysin.
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
LIKELY SAFE ...when used orally in amounts commonly found in foods. The typical diet supplies 2-24 mg of diindolylmethane daily (7170,7176,7664).
POSSIBLY SAFE ...when used orally and appropriately in medicinal doses. Diindolylmethane has been used with apparent safety at a dose of 45 mg daily for up to 6 months or at a higher dose of 100-140 mg daily for up to 3 months (47709,47729,93836,103830).
POSSIBLY UNSAFE ...when used orally in doses of 600 mg daily. In one clinical study, two cases of grade 3 asymptomatic hyponatremia were associated with taking diindolylmethane 600 mg daily (47729).
CHILDREN: LIKELY SAFE
when used orally in amounts commonly found in foods.
The typical diet supplies 2-24 mg of diindolylmethane daily (7170,7176,7664).
PREGNANCY AND LACTATION: LIKELY SAFE
when used orally in amounts commonly found in foods.
The typical diet supplies 2-24 mg of diindolylmethane daily (7170,7176,7664). There is insufficient reliable information available about the safety of diindolylmethane when used in amounts greater than those found in foods during pregnancy and lactation; avoid using.
Below is general information about the interactions of the known ingredients contained in the product Estrovert. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
In vitro evidence suggests that chrysin might inhibit platelet aggregation (7502,42914,42920,42952,93640). Theoretically, taking chrysin with other antiplatelet or anticoagulant drugs might increase the risk of bruising and bleeding in some patients. Some anticoagulant or antiplatelet drugs include aspirin, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.
|
Theoretically, chrysin may have an additive effect on other aromatase inhibitors such as aminoglutethimide (Cytadren), anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara) (7507,7508).
|
In vitro evidence suggests that chrysin might have antiestrogenic activity (42905,42960,42962). Theoretically, use of chrysin with estrogen-containing contraceptive drugs might reduce the efficacy of these drugs.
|
There is some preliminary evidence that chrysin inhibits CYP1A2 isozymes (7503, 8172, 42936, 42956). Theoretically, chrysin might decrease the metabolism of CYP1A2 substrates and increase serum concentrations. However, chrysin was not found to inhibit CYP1A2-dependent caffeine metabolism in animal research (93643). Due to chrysin's low bioavailability and rapid metabolism to glucuronide and sulfate conjugates, this interaction is unlikely (7502,7504,7505,8168,42931,42938,93643). Some substrates of CYP1A2 include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline, zileuton (Zyflo), zolmitriptan (Zomig), and others.
|
In vitro research shows that chrysin and its sulfate conjugate inhibit diclofenac metabolism (106436). It is speculated that chrysin and its sulfate conjugate reduce the metabolism of diclofenac by inhibiting cytochrome P450 2C9 (106436). This effect has not been reported in humans.
|
In vitro evidence suggests that chrysin might have antiestrogenic activity (42905,42960,42962). Theoretically, chrysin might interfere with the effects of hormone therapy.
|
There is some preliminary evidence that chrysin might induce UDP-glucuronosyltransferase 1A1 (UGT1A1) (7504,7513,8170). Theoretically, chrysin might increase the clearance of drugs that are UGT1A1 substrates, such as acetaminophen (Tylenol), estrogens (Estrace, Premarin, others) and oral contraceptives, entacapone (Comtan), irinotecan (Camptosar), and others.
|
In vitro research shows that chrysin and its sulfate and glucuronide conjugates inhibit S-mephenytoin metabolism. It is speculated that chrysin and its conjugates reduce the metabolism of S-mephenytoin by inhibiting cytochrome P450 2C19 (106436). This effect has not been reported in humans.
|
In vitro research shows that chrysin and its sulfate conjugate inhibit testosterone metabolism. It is speculated that chrysin and its sulfate conjugate reduce the metabolism of testosterone by inhibiting cytochrome P450 3A4 (106436). This effect has not been reported in humans.
|
Theoretically, diindolylmethane might lower serum levels of CYP1A2 substrates.
Details
|
Theoretically, diindolylmethane might increase the risk of hyponatremia if used with sodium-depleting diuretics.
Details
Large doses of diindolylmethane (600 mg daily) have been associated with two cases of asymptomatic hyponatremia in clinical research (47729).
|
Theoretically, diindolylmethane might increase or decrease the effects of estrogens.
Details
Diindolylmethane might have mild estrogenic or antiestrogenic effects (7664). Theoretically, large amounts of diindolylmethane might interfere with hormone replacement therapy.
|
Below is general information about the adverse effects of the known ingredients contained in the product Estrovert. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General
...Orally, diindolylmethane is generally well tolerated.
Most Common Adverse Effects:
Orally: Diarrhea, gas, headache, nausea, rash, and vomiting.
Serious Adverse Effects (Rare):
Orally: Drug rash with eosinophilia and systemic symptoms (DRESS).
Dermatologic ...Orally, diindolylmethane can cause rash (47615,93836). In one case report, a patient developed drug rash with eosinophilia and systemic symptoms (DRESS) after consuming a product containing diindolylmethane, vitamin E, and broccoli powder. An allergen patch test was positive for diindolylmethane (93840).
Endocrine ...Orally, diindolylmethane was associated with grade 3 asymptomatic hyponatremia in 2 of 4 patients taking 600 mg daily for 28 days in one clinical study. Hyponatremia was not seen in the 8 patients taking diindolylmethane 150-450 mg daily (47729).
Gastrointestinal ...Orally, diindolylmethane can cause nausea, vomiting, diarrhea, and gas (47652,47676,47709,47729,93836).
Genitourinary ...Orally, diindolylmethane can cause the urine to darken (93836).
Hematologic ...In one case report, a 65-year-old male developed a deep vein thromboembolism (DVT) and bilateral pulmonary emboli (PE) within a few weeks of initiating treatment with diindolylmethane. It is unclear if diindolylmethane contributed to this event; the patient was at increased risk for emboli due to his age, weight, tobacco use, and possible history of pulmonary embolism (93835).
Hepatic ...In one case report, a patient developed drug rash with eosinophilia and systemic symptoms (DRESS), involving elevated liver transaminases, after consuming a product containing diindolylmethane, vitamin E, and broccoli powder. An allergen patch test was positive for diindolylmethane (93840).
Immunologic ...In one case report, a patient developed drug rash with eosinophilia and systemic symptoms (DRESS) after consuming a product containing diindolylmethane, vitamin E, and broccoli powder. The patient developed fever, activated lymphocytes, and swollen lymph nodes. An allergen patch test was positive for diindolylmethane (93840).
Musculoskeletal ...Orally, diindolylmethane has been reported to cause arthralgias (47615).
Neurologic/CNS ...Orally, diindolylmethane can cause headache (47652,47676,93836). One case has reported ischemic stroke in a 38-year-old female with a history of a patent foramen ovale (PFO), traumatic subdural hematoma, right partial hemicraniectomy, and use of several supplements, including 200 mg of diindolylmethane daily, vitamin D3, vitamin K2, elderberry, caffeine, and possibly cannabis (112895). It is unclear if diindolylmethane contributed to this event; the patient was at increased risk for stroke due to PFO and other factors.